Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4.
AIMS: To quantify the 20-ms Pattern Scan Laser (Pascal) panretinal laser photocoagulation (PRP) ablation dosage required for regression of proliferative diabetic retinopathy (PDR), and to explore factors related to long-term regression. METHODS: We retrospectively studied a cohort of patients who p...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1797087145065709568 |
|---|---|
| author | Muqit, M Marcellino, G Henson, D Young, L Turner, G Stanga, P |
| author_facet | Muqit, M Marcellino, G Henson, D Young, L Turner, G Stanga, P |
| author_sort | Muqit, M |
| collection | OXFORD |
| description | AIMS: To quantify the 20-ms Pattern Scan Laser (Pascal) panretinal laser photocoagulation (PRP) ablation dosage required for regression of proliferative diabetic retinopathy (PDR), and to explore factors related to long-term regression. METHODS: We retrospectively studied a cohort of patients who participated in a randomised clinical trial, the Manchester Pascal Study. In all, 36 eyes of 22 patients were investigated over a follow-up period of 18 months. Primary outcome measures included visual acuity (VA) and complete PDR regression. Secondary outcomes included laser burn dosimetry, calculation of retinal PRP ablation areas, and effect of patient-related factors on disease regression. A PDR subgroup analysis was undertaken to assess all factors related to PDR regression according to disease severity. RESULTS: There were no significant changes in logMAR VA for any group over time. In total, 10 eyes (28%) regressed after a single PRP. Following top-up PRP treatment, regression rates varied according to severity: 75% for mild PDR (n=6), 67% for moderate PDR (n=14), and 43% in severe PDR (n=3). To achieve complete disease regression, mild PDR required a mean of 2187 PRP burns and 264 mm(2) ablation area, moderate PDR required 3998 PRP burns and area 456 mm(2), and severe PDR needed 6924 PRP laser burns (836 mm(2); P<0.05). CONCLUSIONS: Multiple 20-ms PRP treatments applied over time does not adversely affect visual outcomes, with favourable PDR regression rates and minimal laser burn expansion over 18 months. The average laser dosimetry and retinal ablation areas to achieve complete regression increased significantly with worsening PDR. |
| first_indexed | 2024-03-07T02:31:51Z |
| format | Journal article |
| id | oxford-uuid:a77edc6e-c524-4a91-aa9f-2d43b4d2fb1f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:31:51Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:a77edc6e-c524-4a91-aa9f-2d43b4d2fb1f2022-03-27T02:55:01ZPascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a77edc6e-c524-4a91-aa9f-2d43b4d2fb1fEnglishSymplectic Elements at Oxford2011Muqit, MMarcellino, GHenson, DYoung, LTurner, GStanga, P AIMS: To quantify the 20-ms Pattern Scan Laser (Pascal) panretinal laser photocoagulation (PRP) ablation dosage required for regression of proliferative diabetic retinopathy (PDR), and to explore factors related to long-term regression. METHODS: We retrospectively studied a cohort of patients who participated in a randomised clinical trial, the Manchester Pascal Study. In all, 36 eyes of 22 patients were investigated over a follow-up period of 18 months. Primary outcome measures included visual acuity (VA) and complete PDR regression. Secondary outcomes included laser burn dosimetry, calculation of retinal PRP ablation areas, and effect of patient-related factors on disease regression. A PDR subgroup analysis was undertaken to assess all factors related to PDR regression according to disease severity. RESULTS: There were no significant changes in logMAR VA for any group over time. In total, 10 eyes (28%) regressed after a single PRP. Following top-up PRP treatment, regression rates varied according to severity: 75% for mild PDR (n=6), 67% for moderate PDR (n=14), and 43% in severe PDR (n=3). To achieve complete disease regression, mild PDR required a mean of 2187 PRP burns and 264 mm(2) ablation area, moderate PDR required 3998 PRP burns and area 456 mm(2), and severe PDR needed 6924 PRP laser burns (836 mm(2); P<0.05). CONCLUSIONS: Multiple 20-ms PRP treatments applied over time does not adversely affect visual outcomes, with favourable PDR regression rates and minimal laser burn expansion over 18 months. The average laser dosimetry and retinal ablation areas to achieve complete regression increased significantly with worsening PDR. |
| spellingShingle | Muqit, M Marcellino, G Henson, D Young, L Turner, G Stanga, P Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4. |
| title | Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4. |
| title_full | Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4. |
| title_fullStr | Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4. |
| title_full_unstemmed | Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4. |
| title_short | Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4. |
| title_sort | pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy manchester pascal study report 4 |
| work_keys_str_mv | AT muqitm pascalpanretinallaserablationandregressionanalysisinproliferativediabeticretinopathymanchesterpascalstudyreport4 AT marcellinog pascalpanretinallaserablationandregressionanalysisinproliferativediabeticretinopathymanchesterpascalstudyreport4 AT hensond pascalpanretinallaserablationandregressionanalysisinproliferativediabeticretinopathymanchesterpascalstudyreport4 AT youngl pascalpanretinallaserablationandregressionanalysisinproliferativediabeticretinopathymanchesterpascalstudyreport4 AT turnerg pascalpanretinallaserablationandregressionanalysisinproliferativediabeticretinopathymanchesterpascalstudyreport4 AT stangap pascalpanretinallaserablationandregressionanalysisinproliferativediabeticretinopathymanchesterpascalstudyreport4 |